Nektar (NKTR) publishes positive Phase 2b REZOLVE-AD 16-week results in The Lancet
Nektar announces publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.